Medivation prostate cancer drug back in the spotlight

In a review of the pricey new prostate cancer treatments hitting the market, Reuters directed its spotlight to Medivation's MDV3100, noting its closely watched status as the biotech readies a crucial interim analysis later this year. For Medivation, which has been bitterly disappointed in its studies of the experimental Alzheimer's treatment Dimebon, the cancer data will present a major catalyst on its stock price. "MDV3100 is certainly promising...but we haven't seen the data yet," says Dr. Elizabeth Plimack, an oncologist at Philadelphia's Fox Chase Cancer Center. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.